ECNP currently supports a variety of major new pan-European research enterprises:
The PRIME (Prevention and Remediation of Insulin Multimorbidity in Europe) project brings together 17 European institutions from nine countries to study the mechanisms underlying mental and somatic insulin-related multimorbidities across the lifespan.
Dysfunctional insulin signalling is a key modulator of mental and non-mental chronic diseases and by investigate these mechanisms the project aims to outline new directions for research and strategies of clinical care, helping to open the way to new treatments, improved public policies and better outcomes for patients.
Learn more about the project by visiting the website and following us on Twitter, LinkedIn and Facebook.
The EQIPD (European Quality in Preclinical Data) project attempts to tackle some of the major problems of developing new drugs to treat brain diseases: the lack of generally agreed principles ensuring the robustness, rigour and validity of research data and the inhibiting effect this has on the development of new medications. The three-year €9.5-million project brings together more than 20 research groups from industry and academia in an effort to establish systematic guidelines, and ensure drug safety, for researchers developing drugs for conditions such as Alzheimer’s.
Stay connected by joining our join our LinkedIn group or follow us on:
The Eat2beNICE (Effects of Nutrition and Lifestyle on Impulsive, Compulsive and Externalising Behaviours) project, funded under the EU’s Horizon 2020 programme, is a pioneering attempt to explore the nervous system highway that connects our brain to our digestive organs and understand how nutrition interacts with mental health, and in particular whether diet can be linked to control disorders such as impulsivity, compulsivity, addiction and aggression. One of the most comprehensive and ambitious research projects of its kind so far undertaken, Eat2beNICE is shining a new light on the connection between what we consume as organisms and how we behave as humans.
Find out more by watching this video.
The c4c (conect4children) project is a major public-private partnership by the Innovative Medicines Initiative 2 Joint Undertaking (IMI2 JU) to improve the clinical trial infrastructure for children in Europe and facilitate the development of new medicines, especially in rare paediatric diseases and high medical need areas. The six-year multimillion-euro project, encompassing 35 academic and 10 industry partners from 20 European countries and more than 50 third parties and around 500 affiliated partners, is a pioneering attempt to develop a sustainable, integrated platform for the efficient and swift delivery of high-quality clinical trials in children and young people across all conditions and phases of the drug development process.
Read the full press release.
Visit this page to discover the latest developments of this project.
The AIMS-2-TRIALS (Autism Innovative Medicine Studies-2-Trials) project is a pan-European attempt to understand the biology of autism to tailor treatments and develop new medicines. The five-year project comprising 48 academic, charity and industry partners from across Europe will conduct a range of studies to explore the biological markers that indicate how autism will develop in individual cases who may ultimately benefit from particular treatments. By building a network of connected centres across Europe and beyond that can test medicines to help with social difficulties, repetitive behaviours and sensory processing, thereby accelerating medicine development, the project aims to put Europe at the forefront of autism treatment research.
The EBRA (European Brain Research Area) project is a catalysing platform for brain research stakeholders – researchers, clinicians, patients, governments, funders and public institutions – to streamline and better co-ordinate brain research across Europe, reducing the fragmentation and duplication of research efforts and fostering synergies at the EU and global level. In addition, over the three-year project span the EBRA consortium will work to identify gaps and areas of strategic opportunity, facilitate the emergence of research projects in specific areas, enable the sharing of data and access to research infrastructures, increase the visibility of the brain research portfolio as a whole, and promote the uptake of EBRA results to key stakeholders.
The PRISM (Psychiatric Ratings using Intermediate Stratified Markers) project, funded under the Innovative Medicines Initiative (IMI), is a bold attempt by the European Union to foster ground-breaking cross-sector collaboration. A landmark multimillion-euro project to find the biological basis for social withdrawal, PRISM seeks to open a window onto the underlying pathologies that connect such major disorders as depression, schizophrenia and Alzheimer’s. By looking for a common biological mechanism underlying behavioural markers – in this case social withdrawal – that can link apparently very different diseases, the project seeks to develop a new understanding of brain disorders and the processes that will drive them, and open up new avenues of treatment. Duration of phase one of the project was 3 years (2016-2019).